Drug Profile

HSK 46575

Alternative Names: HSK-46575

Latest Information Update: 27 Jun 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Haisco Pharmaceutical Group
Class Antineoplastics
Mechanism of Action Cholesterol side chain cleavage enzyme inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Prostate cancer

Most Recent Events

25 Apr 2025 Preclinical trials in Prostate cancer in China (PO) prior to December 2024
25 Apr 2025 Pharmacodynamics, pharmacokinetic and adverse events data from preclinical trial in Prostate cancer presented at the 116^th Annual Meeting of the American Association for Cancer Research (AACR-2025)
18 Dec 2024 Phase-I clinical trials in Prostate cancer (Hormone refractory, Metastatic disease) in China (PO) (NCT07007910)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com